U.S. markets open in 3 hours 34 minutes

TMS Co., Ltd. (4891.T)

Tokyo - Tokyo Delayed Price. Currency in JPY
525.00-12.00 (-2.23%)
At close: 03:15PM JST

TMS Co., Ltd.

11th Floor, Keio Fuchu 1 Chome Building
1-9 Fuchu-cho
Fuchu 183-0055
81 42 307 7480

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Takuro WakabayashiPres & Representative DirectorN/AN/AN/A
Go ItoCFO & Board MemberN/AN/AN/A
Koji OheGen. CounselN/AN/AN/A
Noriaki Inamura Ph.D.Head of R&D and Board MemberN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.


TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. The company was incorporated in 2005 and is headquartered in Fuchu, Japan.

Corporate Governance

TMS Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.